Navidea receives Fast Track designation for Lymphoseek injection

[News]

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

More... (http://www.news-medical.net/news/20131211/Navidea-receives-Fast-Track-designation-for-Lymphoseek-injection.aspx)